LUNG | Pulmonx Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.19 - 8.57
52 Week Range	5.46 - 14.84
Beta	0.55
Implied Volatility	369.82%
IV Rank	12.91%
Day's Volume	188,580
Average Volume	335,751
Shares Outstanding	39,152,600
Market Cap	323,792,002
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2020-10-01

Valuation
Profitability
Growth
Health
P/E Ratio	-5.51
Forward P/E Ratio	N/A
EPS	-1.50
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	279
Country	USA
Website	LUNG

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

LUNG's peers: AHCO, AORT, APYX, ATEC, AXDX, AXGN, AXNX, BRKR, CERS, CLPT, SMLR, CNMD, CTKB, CTSO, CUTR, CVRX, ELMD, DCTH, ESTA, FNA, HYPR, INGN, IRIX, IRMD, ITGR, KIDS, LIVN, LNSR, LUCD, OFIX, NPCE, NUVA, SIBN, RXST, TMCI, OSA, SRDX, MXCT, NVNO, NVRO, OM, PRCT, PROF, QDEL, QIPT, QTRX, RBOT, RCEL, RPID, SGHT, SILK, SRTS, TCMD, TELA, TMDX, UFPT, VMD, XAIR, ZBH, ZIMV, CATX

*Chart delayed

Analyzing fundamentals for LUNG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see LUNG Fundamentals page.

Watching at LUNG technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on LUNG Technicals page.